scholarly journals Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome

2018 ◽  
Author(s):  
Roman Mylonas ◽  
Ilan Beer ◽  
Christian Iseli ◽  
Chloe Chong ◽  
HuiSong Pak ◽  
...  

AbstractSpliced peptides are short protein fragments spliced together in the proteasome by peptide bond formation. True estimation of the contribution of proteasome-spliced peptides (PSPs) to the global Human Leukocyte Antigen (HLA) ligandome is critical. A recent study suggested that PSPs contribute up to 30% of the HLA ligandome. We performed a thorough reanalysis of the reported results using multiple computational tools and various validation steps and concluded that only a fraction of the proposed PSPs passes the quality filters. To better estimate the actual number of PSPs, we present an alternative workflow. We performed de-novo sequencing of the HLA-peptide spectra and discarded all de-novo sequences found in the UniProt database. We checked whether the remaining de-novo sequences could match spliced peptides from human proteins. The spliced sequences were appended to the UniProt fasta file, which was searched by two search tools at a FDR of 1%. We find that maximally 2-4% of the HLA ligandome could be explained as spliced protein fragments. The majority of these potential PSPs have good peptide-spectrum match properties and are predicted to bind the respective HLA molecules. However, it remains to be shown how many of these potential PSPs actually originate from proteasomal splicing events.

2008 ◽  
Vol 88 (5) ◽  
pp. 602-605
Author(s):  
Tohru Inaba ◽  
Hiroshi Nishimura ◽  
Junko Saito ◽  
Yoko Yamane ◽  
Takuya Nakatani ◽  
...  

2019 ◽  
Author(s):  
Thomas F. Martinez ◽  
Qian Chu ◽  
Cynthia Donaldson ◽  
Dan Tan ◽  
Maxim N. Shokhirev ◽  
...  

Protein-coding small open reading frames (smORFs) are emerging as an important class of genes, however, the coding capacity of smORFs in the human genome is unclear. By integrating de novo transcriptome assembly and Ribo-Seq, we confidently annotate thousands of novel translated smORFs in three human cell lines. We find that smORF translation prediction is noisier than for annotated coding sequences, underscoring the importance of analyzing multiple experiments and footprinting conditions. These smORFs are located within non-coding and antisense transcripts, the UTRs of mRNAs, and unannotated transcripts. Analysis of RNA levels and translation efficiency during cellular stress identifies regulated smORFs, providing an approach to select smORFs for further investigation. Sequence conservation and signatures of positive selection indicate that encoded microproteins are likely functional. Additionally, proteomics data from enriched human leukocyte antigen complexes validates the translation of hundreds of smORFs and positions them as a source of novel antigens. Thus, smORFs represent a significant number of important, yet unexplored human genes.


Immunology ◽  
2018 ◽  
Vol 154 (3) ◽  
pp. 331-345 ◽  
Author(s):  
Lena Katharina Freudenmann ◽  
Ana Marcu ◽  
Stefan Stevanović

Biomedicines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 72 ◽  
Author(s):  
Covadonga López del Moral Cuesta ◽  
Sandra Guiral Foz ◽  
David Gómez Pereda ◽  
José Luis Pérez Canga ◽  
Marina de Cos Gómez ◽  
...  

Immunosuppression withdrawal after graft failure seems to favor sensitization. A high percentage of calculated panel-reactive antibody (cPRA) and the development of de novo donor specific antibodies (dnDSA) indicate human leukocyte antigen (HLA) sensitization and may hinder the option of retransplantation. There are no established protocols on the immunosuppressive treatment that should be maintained after transplant failure. A retrospective analysis including 77 patients who lost their first renal graft between 1 January 2006–31 December 2015 was performed. Two sera were selected per patient, one immediately prior to graft loss and another one after graft failure. cPRA was calculated by Single Antigen in all patients. It was possible to analyze the development of dnDSA in 73 patients. By multivariate logistic regression analysis, the absence of calcineurin inhibitor (CNI) at 6 months after graft failure was related to cPRA > 75% (OR 4.8, CI 95% 1.5–15.0, p = 0.006). The absence of calcineurin inhibitor (CNI) at 6 months after graft loss was significantly associated with dnDSA development (OR 23.2, CI 95% 5.3–100.6, p < 0.001). Our results suggest that the absence of CNI at the sixth month after graft loss is a risk factor for sensitization. Therefore, maintenance of an immunosuppressive regimen based on CNI after transplant failure should be considered when a new transplant is planned, since it seems to prevent HLA allosensitization.


2018 ◽  
Vol 33 (8) ◽  
pp. 1472-1480 ◽  
Author(s):  
Ankit Sharma ◽  
Joshua R Lewis ◽  
Wai H Lim ◽  
Suetonia Palmer ◽  
Giovanni Strippoli ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document